GlassScriptPhysician profile
Resmi Bhashiam
NPI 1891200580
$2,765.53
in general payments reported to CMS, 2019-2025
17 companies · $858 in 2025
The $858 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4.52 · 2022: $11.80 · 2024: $1,891 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $455.88 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $372.80 | 2024-2025 | Uzedy, Austedo Xr |
| Gilead Sciences, INC. | $249.99 | 2024 | Epclusa |
| Actelion Pharmaceuticals US, INC. | $246.09 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $190.46 | 2024-2025 | |
| Medtronic, INC. | $144.00 | 2024 | Interstim |
| Abiomed | $139.14 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $134.59 | 2024 | Spravato |
| Alnylam Pharmaceuticals INC. | $126.93 | 2024 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $123.75 | 2024 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $116.87 | 2025 | |
| Viiv Healthcare Company | $107.10 | 2024 | Dovato |
| Axsome Therapeutics, INC. | $95.04 | 2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $11.80 | 2022 | |
| Genentech USA, INC. | $4.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Resmi Bhashiam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.